FDA Inspection
Genzyme CorporationGenzyme Corporation – FDA Inspection, Feb 14, 2025
Record Details
This FDA Inspection record concerns Genzyme Corporation, with an inspection on February 14, 2025, issued by the New England District Office, covering biologics.
View Company Profile
ID · abd12bcb-8957-45b8-b0a5-611ccb2bdf41
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1261312
- FDA center
- Biologics
- Project area
- Blood and Blood Products
FDA Citations
3- 21 CFR 211.130(d)Examination of packaging and labeling
- 21 CFR 211.130Procedures are written, and followed
- 21 CFR 211.192No written record of investigation
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Genzyme Corporation
7| Date | Classification | Office | Project area |
|---|---|---|---|
| August 14, 2025 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 28, 2020 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 19, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 18, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 18, 2014 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Genzyme Corporation
- FDA Inspection 1281578 - 2025-08-14
- FDA Inspection 1120993 - 2020-02-28
- FDA Inspection 1062695 - 2018-07-19
- FDA Inspection 985381 - 2016-08-18
- FDA Inspection 896910 - 2014-09-18
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.